Kraiczy P, Skerka C, Kirschfink M, Brade V, Zipfel P F
Institute of Medical Microbiology, University Hospital of Frankfurt, Frankfurt, Germany.
Eur J Immunol. 2001 Jun;31(6):1674-84. doi: 10.1002/1521-4141(200106)31:6<1674::aid-immu1674>3.0.co;2-2.
To understand immune evasion mechanisms of Borrelia burgdorferi we compared serum-resistant B. afzelii and serum-sensitive B. garinii isolates for their capacity toacquire human complement regulators. Here we demonstrate that the two borrelial genospecies show different binding of the two important human complement regulators, FHL-1/reconectin and Factor H. All serum-resistant B. afzelii isolates bound FHL-1/reconectin and also Factor H, and all analyzed serum-sensitive B. garinii isolates showed no or a significantly lower binding activity. Using recombinant deletion mutants, the binding domains were localized to the C terminus of FHL-1/reconectin to short consensus repeats 5-7. The borrelial binding proteins were located in the surface of the bacteria as demonstrated by immunofluorescence staining of intact, serum-exposed bacteria and by enrichment of outer membrane proteins. The surface-attached complement regulators maintained complement regulatory activity as demonstrated in a cofactor assay. By ligand blotting two different borrelial binding proteins were identified that were responsible for the surface attachment of FHL-1/reconectin and Factor H. These borrelial complement regulators acquiring surface proteins (CRASP) were further characterized as either CRASP-1, a 27.5-kDa molecule which preferentially binds FHL-1/reconectin and which was present in all serum-resistant borreliae, or CRASP-2, a 20/21-kDa protein which interacts preferentially with Factor H and the expression of which was more restricted, being detected in four of the six isolates analyzed. In summary, we describe a new immune evasion mechanism of B. burgdorferi, as these bacteria acquire human complement regulators to control complement activation on their surface and to prevent formation of toxic activation products.
为了解伯氏疏螺旋体的免疫逃逸机制,我们比较了血清抗性的阿氏疏螺旋体和血清敏感的伽氏疏螺旋体分离株获取人类补体调节蛋白的能力。在此我们证明,这两种疏螺旋体基因型对两种重要的人类补体调节蛋白,即FHL-1/再结合蛋白和H因子,表现出不同的结合情况。所有血清抗性的阿氏疏螺旋体分离株均能结合FHL-1/再结合蛋白以及H因子,而所有分析的血清敏感的伽氏疏螺旋体分离株均未表现出或仅表现出显著较低的结合活性。使用重组缺失突变体,发现结合结构域定位于FHL-1/再结合蛋白的C末端至短共有重复序列5-7。通过对完整的、暴露于血清的细菌进行免疫荧光染色以及对外膜蛋白进行富集,证明疏螺旋体结合蛋白位于细菌表面。如在辅因子分析中所示,表面附着的补体调节蛋白保持补体调节活性。通过配体印迹法鉴定出两种不同的疏螺旋体结合蛋白,它们负责FHL-1/再结合蛋白和H因子的表面附着。这些获取表面蛋白的疏螺旋体补体调节蛋白(CRASP)被进一步鉴定为CRASP-1,一种27.5 kDa的分子,优先结合FHL-1/再结合蛋白,存在于所有血清抗性疏螺旋体中;或CRASP-2,一种20/21 kDa的蛋白,优先与H因子相互作用且其表达更具限制性,在分析的六个分离株中的四个中检测到。总之,我们描述了伯氏疏螺旋体一种新的免疫逃逸机制,因为这些细菌获取人类补体调节蛋白以控制其表面的补体激活并防止有毒激活产物的形成。